



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Lipoprotein(a), genetics, and coronary artery disease

Mark Trinder
Graduate Student
Liam Brunham

Monday, February 1st, 2021
9:00 – 10:00 a.m.

Zoom Video Conference

(Meeting ID: 693 1997 7044; Passcode: 030679)

“Lipoprotein(a) is a clinically underappreciated plasma lipoprotein which is composed of a low-density lipoprotein particle (containing apolipoprotein B) that is linked to apolipoprotein(a). Circulating levels of lipoprotein(a) are highly heritable, elevated levels of lipoprotein(a) are common, and lipoprotein(a) is independently associated with increased risk of coronary artery disease. Apolipoprotein B is believed to be a key unifying feature of all atherogenic lipoproteins. However, it is unclear to what extent non-apolipoprotein B-mediated mechanisms of lipoprotein(a) contribute to the pathogenicity of coronary artery disease in humans (i.e. apolipoprotein(a), propensity to become oxidized and cause inflammation). Here, we used human genetics to investigate whether like low-density lipoprotein cholesterol, apolipoprotein B is sufficient to explain the risk of coronary artery disease associated with lipoprotein(a) particles. We also sought to determine whether a polygenic score for lipoprotein(a), has clinical utility in assessing risk of coronary artery disease compared with and in addition to direct measurement of lipoprotein(a).”

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada



a place of mind

THE  LUNG ASSOCIATION™
British Columbia



HEART &
STROKE
FOUNDATION
OF BC & YUKON

Finding answers. For life.